Literature DB >> 24526773

Bendamustine: the remedy that came in from the cold.

Suzanne Lentzsch1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24526773     DOI: 10.1182/blood-2013-12-539817

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

1.  Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Authors:  Philippe Rodon; Cyrille Hulin; Brigitte Pegourie; Mourad Tiab; Bruno Anglaret; Lotfi Benboubker; Henry Jardel; Olivier Decaux; Brigitte Kolb; Murielle Roussel; Laurent Garderet; Xavier Leleu; Olivier Fitoussi; Carine Chaleteix; Philippe Casassus; Pascal Lenain; Bruno Royer; Anne Banos; Riad Benramdane; Pascale Cony-Makhoul; Mamoun Dib; Jean Fontan; Anne-Marie Stoppa; Catherine Traullé; Jean-Pierre Vilque; Marie-Odile Pétillon; Claire Mathiot; Thomas Dejoie; Hervé Avet-Loiseau; Philippe Moreau
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

2.  Esters of Bendamustine Are by Far More Potent Cytotoxic Agents than the Parent Compound against Human Sarcoma and Carcinoma Cells.

Authors:  Stefan Huber; Johannes Philip Huettner; Kristina Hacker; Günther Bernhardt; Jörg König; Armin Buschauer
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

3.  Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma.

Authors:  Claudio Cerchione; Davide Nappi; Maria Di Perna; Irene Zacheo; Anna Emanuele Pareto; Marco Picardi; Lucio Catalano; Fabrizio Pane
Journal:  Case Rep Hematol       Date:  2016-10-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.